{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Labrador J"],"funding":["Instituto de Salud Carlos III"],"pagination":["1734"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8997036"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(7)"],"pubmed_abstract":["The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was 68 years, most were at high risk, 61% received ≥2 therapies for AML, 49% had received hypomethylating agents, and ECOG was ≥2 in 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi), was 12.4%. Additionally, 10.4% experienced partial response (PR). The CR/CRi was higher in combination with azacitidine (AZA; 17.9%) than with decitabine (DEC; 6.7%) and low-dose cytarabine (LDAC; 0%). Mutated NPM1 was associated with incre"],"journal":["Cancers"],"pubmed_title":["Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience."],"pmcid":["PMC8997036"],"funding_grant_id":["CD21/00022"],"pubmed_authors":["Conde-Royo D","Foncillas MA","Recio I","Garcia-Fortes M","Cuello R","Sanz MA","de Laiglesia A","Vall-Llovera F","Olivier C","Seri-Merino C","Vives S","Munoz-Garcia C","Bienert-Garcia A","de Miguel D","Vidriales MB","Benzo-Callejo G","Sayas MJ","Labrador J","Perez-Encinas M","Sanchez-Sanchez MJ","Tormo M","Martinez-Cuadron D","Vahi M","Colorado M","Montesinos P","Rodriguez-Medina C","Roldan-Perez A","Saiz-Rodriguez M"],"additional_accession":[]},"is_claimable":false,"name":"Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.","description":"The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was 68 years, most were at high risk, 61% received ≥2 therapies for AML, 49% had received hypomethylating agents, and ECOG was ≥2 in 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi), was 12.4%. Additionally, 10.4% experienced partial response (PR). The CR/CRi was higher in combination with azacitidine (AZA; 17.9%) than with decitabine (DEC; 6.7%) and low-dose cytarabine (LDAC; 0%). Mutated NPM1 was associated with incre","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-06-18T03:14:50.827Z","creation":"2025-04-04T12:40:59.55Z"},"accession":"S-EPMC8997036","cross_references":{"pubmed":["35406512"],"doi":["10.3390/cancers14071734"]}}